UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease

International journal of molecular sciences, 2022-02, Vol.23 (5), p.2668

2022

Volltextzugriff (PDF)

Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis

Gut, 2020-03, Vol.69 (3), p.551

2020

Volltextzugriff (PDF)

Chemokine (C‐C motif) receptor 2–positive monocytes aggravate the early phase of acetaminophen‐induced acute liver injury

Hepatology (Baltimore, Md.), 2016-11, Vol.64 (5), p.1667-1682

2016

Volltextzugriff (PDF)

Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury

PloS one, 2017-09, Vol.12 (9), p.e0184694-e0184694

2017

Volltextzugriff (PDF)

Serum CXCL5 Detects Early Hepatocellular Carcinoma and Indicates Tumor Progression

International journal of molecular sciences, 2023-03, Vol.24 (6), p.5295

2023

Volltextzugriff (PDF)

Monocyte dysregulation: consequences for hepatic infections

Seminars in immunopathology, 2021-08, Vol.43 (4), p.493-506

2021

Volltextzugriff (PDF)

CT-based determination of excessive visceral adipose tissue is associated with an impaired survival in critically ill patients

PloS one, 2021-04, Vol.16 (4), p.e0250321-e0250321

2021

Volltextzugriff (PDF)

Cell type‐specific actions of thyroid hormones in nonalcoholic steatohepatitis and liver fibrosis

Liver international, 2024-02, Vol.44 (2), p.275-278

2024

Volltextzugriff (PDF)

Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)

Expert opinion on investigational drugs, 2023-06, Vol.32 (6), p.451-461

2023

Volltextzugriff (PDF)

Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?

Expert opinion on pharmacotherapy, 2024-06, Vol.25 (9), p.1249-1263

2024

Volltextzugriff (PDF)

Editorial: prevalence, progression rates and mortality predictors of non‐alcoholic fatty liver disease reflected by German statutory health insurance data

Alimentary pharmacology & therapeutics, 2020-10, Vol.52 (8), p.1412-1413

2020

Volltextzugriff (PDF)

Repair macrophages in acute liver failure

Gut, 2018-02, Vol.67 (2), p.202

2018

Volltextzugriff (PDF)

Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis

Journal of clinical medicine, 2022-04, Vol.11 (9), p.2479

2022

Volltextzugriff (PDF)

Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial

Journal of global antimicrobial resistance., 2023-03, Vol.32, p.44-47

2023

Volltextzugriff (PDF)

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH

Journal of hepatology, 2023-08, Vol.79 (2), p.552-566

2023

Volltextzugriff (PDF)

Association of Serum Calprotectin Concentrations with Mortality in Critically Ill and Septic Patients

Diagnostics (Basel), 2020-11, Vol.10 (11), p.990

2020

Volltextzugriff (PDF)

Efruxifermin, an investigational treatment for fibrotic or cirrhotic non-alcoholic steatohepatitis (NASH)

Expert opinion on investigational drugs, 2023-06

2023

Volltextzugriff (PDF)

THU-291-YI Cellular senescence is a common hallmark in diverse models of steatotic liver diseases

Journal of hepatology, 2024-06, Vol.80, p.S594-S595

2024

Volltextzugriff (PDF)

FRI-457 CXCL12 restricts hepatocellular carcinoma progression by shaping the tumor microenvironment in liver fibrosis

Journal of hepatology, 2024-06, Vol.80, p.S414-S414

2024

Volltextzugriff (PDF)

Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis

Expert review of endocrinology & metabolism, 2022-09, Vol.17 (5), p.425-434

2022

Volltextzugriff (PDF)

PS-007-Differential therapeutic effects of pan- and single PPAR agonists on steatosis, inflammation, macrophage composition and fibrosis in a murine model of non-alcoholic steatohepatitis

Journal of hepatology, 2019-04, Vol.70 (1), p.e8-e9

2019

Volltextzugriff (PDF)

AS016 - Combination therapy with a dual CCR2/CCR5 antagonist and a FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis

Journal of hepatology, 2020-08, Vol.73, p.S13-S13

2020

Volltextzugriff (PDF)

Combination therapy with a dual CCR2/CCR5 antagonist and a FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis

Journal of hepatology, 2020-08, Vol.73, p.S13

2020

Volltextzugriff (PDF)

Diagnosis and treatment of severe acute pancreatitis in critical care

Deutsche medizinische Wochenschrift (1946), 2020-06, Vol.145 (12), p.850

2020

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Aktive Filter

ThemaMetabolism

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(24)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease

Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis

Chemokine (C‐C motif) receptor 2–positive monocytes aggravate the early phase of acetaminophen‐induced acute liver injury

Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury

Serum CXCL5 Detects Early Hepatocellular Carcinoma and Indicates Tumor Progression

Monocyte dysregulation: consequences for hepatic infections

CT-based determination of excessive visceral adipose tissue is associated with an impaired survival in critically ill patients

Cell type‐specific actions of thyroid hormones in nonalcoholic steatohepatitis and liver fibrosis

Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)

Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?

Editorial: prevalence, progression rates and mortality predictors of non‐alcoholic fatty liver disease reflected by German statutory health insurance data

Repair macrophages in acute liver failure

Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis

Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH

Association of Serum Calprotectin Concentrations with Mortality in Critically Ill and Septic Patients

Efruxifermin, an investigational treatment for fibrotic or cirrhotic non-alcoholic steatohepatitis (NASH)

THU-291-YI Cellular senescence is a common hallmark in diverse models of steatotic liver diseases

FRI-457 CXCL12 restricts hepatocellular carcinoma progression by shaping the tumor microenvironment in liver fibrosis

Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis

PS-007-Differential therapeutic effects of pan- and single PPAR agonists on steatosis, inflammation, macrophage composition and fibrosis in a murine model of non-alcoholic steatohepatitis

AS016 - Combination therapy with a dual CCR2/CCR5 antagonist and a FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis

Combination therapy with a dual CCR2/CCR5 antagonist and a FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis

Diagnosis and treatment of severe acute pancreatitis in critical care

Aktive Filter

Suchergebnisse filtern